All Eli Lilly articles
-
NewsEli Lilly acquires CrossBridge Bio’s dual-payload ADC platform
Eli Lilly has acquired CrossBridge Bio, advancing a dual-payload antibody-drug conjugate platform developed at UTHealth Houston. The technology aims to deliver chemotherapy more precisely to tumour cells whilst minimising damage to healthy tissue, with lead candidate CBB-120 now positioned for accelerated clinical development.